Phase 2
N=52
ESBA1008 Microvolume Study
Exudative Age-Related Macular Degeneration
Bottom Line
View on ClinicalTrials.gov: NCT01849692 ↗Enrolled (actual)
52
Serious AEs
1.9%
Results posted
Feb 2016
Primary outcome: Primary: Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 — 70; 60; 80; 60 percentage of responders
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- ESBA1008 solution (Drug); Ranibizumab (Drug)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Alcon Research
- Primary completion
- Jan 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Responders Based on CSFT and BCVA Outcomes at Day 14 and Day 28 |
70; 60; 80; 60; 100; 100 | — |
| SECONDARY Change From Baseline in BCVA, Cohort 1 |
4.5; 4.7; 5.9; 6.3; 7.7; 10.3 | — |
| SECONDARY Change From Baseline in BCVA, Cohort 2 |
2.4; 7.0; 4.8; 7.3; 5.5; 10.3 | — |
| SECONDARY Change From Baseline in BCVA, Cohort 3 |
10.3; 5.0; 9.8; 7.3; 13.5; 5.0 | — |
| SECONDARY Change From Baseline in BCVA, Cohort 4 |
3.2; 9.3; 7.1; 12.3; 4.7; 11.7 | — |
| SECONDARY Change From Baseline in CSFT, Cohort 1 |
-114.0; -99.7; -188.2; -130.3; -182.0; -175.3 | — |
| SECONDARY Change From Baseline in CSFT, Cohort 2 |
-57.9; -87.7; -96.5; -116.0; -104.9; -142.3 | — |
| SECONDARY Change From Baseline in CSFT, Cohort 3 |
-93.4; -54.0; -126.8; -85.7; -163.1; -104.0 | — |
| SECONDARY Change From Baseline in CSFT, Cohort 4 |
-102.8; -105.3; -119.9; -194.3; -125.1; -187.3 | — |
Summary
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
Eligibility Criteria
Inclusion Criteria
- Sign informed consent document;
- Able to make the required study visits and follow instructions;
- Age-related macular degeneration in the study eye;
- Visual acuity within protocol-specified range;
- 340 μm minimal central subfield thickness (CSFT; Spectralis Equivalent)
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Both eyes: Any active infection or inflammation;
- Study eye: Any treatment for exudative age-related macular degeneration (AMD) other than vitamin supplements;
- Study eye: Any current or history of macular or retinal disease;
- Study eye: Any concurrent intraocular condition such as cataract or diabetic retinopathy that, in the opinion of the Investigator, could either require medical or surgical intervention during the course of the study to prevent or treat visual loss;
- Study eye: Other ocular conditions or diseases that, in the opinion of the Investigator, could compromise visual acuity;
- Study Eye: Uncontrolled glaucoma;
- History of a medical condition that, in the opinion of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product;
- Women of childbearing potential who are lactating, pregnant, planning to become pregnant, or not using adequate birth control methods for the duration of the study;
- Intraocular surgery within 3 months of baseline;
- Study eye: Any history or current evidence of retinal angiomatous proliferation (RAP) lesions based on clinical exam;
- Other protocol-defined exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT01849692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.